SpaceX jumped 19% on Friday in its Nasdaq debut after the biggest initial public offering ever. The stock closed at around $161, valuing the company at $2.1 trillion, and kept rallying in extended trading adding about another $100 billion to its market cap. Read...
Read MoreRows of solid carbon blocks sit inside an insulated facility in Big Stone City, South Dakota — quietly holding heat that, hours earlier, was surplus electricity from regional wind turbines. There are no spinning turbines here, no flowing water, no chemical reactions. Just stored warmth, waiting to work. Read more...
Read MoreBOLOGNA, Italy–(BUSINESS WIRE)–The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe’s leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. Read...
Read MoreNEW YORK, June 11, 2026 /PRNewswire/ — Clinch has long helped marketers maximize the relevance and value of every advertising impression through intelligent creative and omnichannel orchestration. Today, the company is expanding that foundation into AI-era brand management with the launch of an operational Generative Engine Optimization (GEO) solution. Powered by Whitebox, a company specializing in AI visibility intelligence and optimization across generative search platforms, the new offering enables marketers to truly understand how their brand shows up in the new age of AI discovery, and leverage those insights to improve discoverability, and inform omnichannel content and creative decisioning, extending Clinch’s role beyond paid media execution into the broader management of owned and earned brand narratives. Read more...
Read MoreJerusalem, June 11, 2026 — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”, or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company to proceed with enrollment of the final seven patients in its U.S. REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial, following the FDA’s review of a pre-specified interim safety report of the first three patients treated in the trial. The Company intends to recommence patient recruitment immediately, on the back of tremendous clinical interest in continuing the trial. Read...
Read More
